Q1 2022

Filed May 23, 2022 · 10-Q · 53 days after period end · 0001493152-22-014681

Q1 2022 · 10-Q

Revenue—

Net Income

-$4.85M

N/M vs Q1 2021

EPS, diluted—

Operating Income-$4,344,206N/M

Operating Cash Flow-$962,668N/M

Same quarter

Metric	Q1 2022	Q1 2021	Q1 2020	Q1 2019
Revenue	—	—	$340.86K	—
Net Income	-$4.85M	-$2.80M	-$4.66M	-$976.06K
EPS Diluted	—	-$0.03	-$0.05	-$0.14

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR